Rhythm Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
By licensing out two of its peptides for metabolic and gastrointestinal disorders, Ipsen enabled the launch of Rhythm Pharmaceuticals Inc. Rhythm will build a largely virtual company around Ipsen's molecules and IP related to analogs of the peptide hormones ghrelin and MC4, which regulate food intake, energy homeostasis, and gastrointestinal function. Rhythm's lead GI compound RM-131-is a potential treatment for gastrointestinal motility disorders such as postoperative ileus and diabetic gastroparesis. The new company's lead metabolic compound RM-493, which specifically targets the melanocortin-4 receptor-is a potential treatment for obesity, diabetes, and related metabolic disorders.
You may also be interested in...
Start-Up Previews (06/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. "Altering The Insulin Resistance System" features profiles of Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia BIotech and Rhythm Pharmaceuticals. Plus these Start-Ups Across Health Care: nContact Surgical, NormOxys and Thermopeutix.
Catabasis Pharmaceuticals Inc.
Catabasis Pharmaceuticals is drawing on research showing that salicylate, a close relative of aspirin, improves glucose homeostasis in people living with type 2 diabetes. Catabasis hopes that by combining salicylate with optimized forms of omega-3 fatty acids, it can come up with a safe and reimbursable drug that simultaneously inhibits pro-inflammatory pathways and activates anti-inflammatory pathways, with benefits for diabetes, dyslipidemia, and inflammatory diseases.
Altering The Insulin Resistance System
With the US deeply mired in an obesity epidemic, a growing aging population throughout the developed world, and rising rates of obesity, the market for therapeutic agents for metabolic disorders and especially type 2 diabetes will continue to grow. Little wonder that many emerging companies are pursuing innovative metabolic, obesity, and type 2 diabetes programs to supplement those of Big Pharma. We profile four of them in this issue: Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia Biotech and Rhythm Pharmaceuticals.